Potent and competitive pituitary adenylate cyclase-activating polypeptide receptor (PAC)1 antagonist (IC50 = 2nM). Inhibits PACAP(1-27)-induced stimulation of adenylate cyclase (Ki = 1.5nM). Antitumor activity in vivo.